Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Gilead Sciences Inc.
Sponsor

Gilead Sciences Inc.

United States 333 Lakeside Drive, 94404-1147, United States

About the sponsor

Research activity centers on oral maintenance and switching regimens for virologically suppressed people with HIV-1 infection, treatment-naive populations, and prevention strategies for individuals at risk of acquisition. The portfolio also includes pediatric and adolescent studies, reflecting interest across age groups and clinical settings.

  • Virologically suppressed people with HIV-1
  • Pre-exposure prophylaxis
  • Pediatric and adolescent HIV care
  • Antiretroviral switching strategies

Key areas include lenacapavir, islatravir, bictegravir, emtricitabine, tenofovir alafenamide, and combination regimens designed to support long-term HIV management.

About Specializations

Gilead Sciences Inc. runs clinical trials in conditions such as HIV infection, Non-small cell lung cancer, Triple negative breast cancer, Hepatitis D, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

45 clinical trials

HIV infection

Recruiting

Switching to Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults with HIV-1: A Phase 3 Randomized Study

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abacavir
  • Sponsor:Gilead Sciences Inc.

HIV infection

Recruiting

Switching to lenacapavir-based drug combination vs cabotegravir-based drug combination in virologically suppressed adults with HIV-1

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Gilead Sciences Inc.

Oesophageal adenocarcinoma

Recruiting

Study of denikitug alone or with drug combination in adults with HER2‑negative metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Gilead Sciences Inc.

Hepatitis D+1

Recruiting

Study of GS-4321 for Healthy People and Patients With Chronic Hepatitis Delta Virus Infection

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:GS-4321
  • Sponsor:Gilead Sciences Inc.

Ovarian endometrioid carcinoma

Recruiting

A Study Testing TUB-040 Combined with Standard Cancer Drugs for Patients with High-Grade Epithelial Serous or Endometrioid Ovarian Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:TUB-040
  • Sponsor:Gilead Sciences Inc.

Squamous cell carcinoma of head and neck+1

Recruiting

Testing the Safety and Effects of TUB-030 in Patients with Advanced Head and Neck Cancer or Non-Small-Cell Lung Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:TUB-030
  • Sponsor:Gilead Sciences Inc.

Primary biliary cholangitis

Recruiting

Study of Seladelpar Treatment in Patients with Primary Biliary Cholangitis and Compensated Cirrhosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Seladelpar
  • Sponsor:Gilead Sciences Inc.

Small cell lung cancer extensive stage

Recruiting

Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Gilead Sciences Inc.

Ovarian cancer+2

Recruiting

Study on the Safety and Tolerability of TUB-040 for Patients with Platinum-Resistant Ovarian Cancer or Relapsed/Refractory Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:TUB-040
  • Sponsor:Gilead Sciences Inc.

HIV infection

Recruiting

Study of Bictegravir and Lenacapavir for Children and Adolescents with HIV-1

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

Triple negative breast cancer

Recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Gilead Sciences Inc.

HIV infection

Not yet recruiting

Safety and efficacy of GS-3242 drug combination compared with standard drug combination in treatment‑naive adults with HIV‑1

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.